← Back to Search

Health Information Exchange Platform for Improving Patient Transfers

N/A
Waitlist Available
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age greater than or equal to 18 years old
Be older than 18 years old
Must not have
Direct admission from home/clinic
Age < 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time-of-day and date of transfer to time-of-day and date of hospital discharge
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking at whether or not an interoperable health information exchange platform can help reduce patient harm during inter-hospital transfers.

Who is the study for?
This trial is for adults over 18 who are admitted to general medicine, cardiology, oncology, or ICU services at Brigham and Women's Hospital and transferred from one of these hospitals: Brigham and Women's Faulkner Hospital, South Shore Hospital, Milford Regional Medical Center. It excludes those under 18 or admitted through ER or directly from home/clinic.
What is being tested?
The trial is testing a Health Information Exchange (HIE) platform designed to improve the transfer of patient information between hospitals. The goal is to see if this system reduces medical errors by providing better access to clinical data during inter-hospital transfers.
What are the potential side effects?
Since this trial involves an information technology intervention rather than a medication or medical procedure, traditional physical side effects are not applicable. However, there may be technical issues or challenges in using the platform that could indirectly affect patient care.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am coming directly from home or a clinic.
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 hours after transfer
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 72 hours after transfer for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Total clinician-reported medical errors
Secondary study objectives
Ameliorable clinician-reported adverse events
Clinician-reported medical errors attributable to poor information exchange
Clinician-reported quality of clinical information available
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
The intervention arm will include all included patient transfers from the 3 participating transfer hospitals to the 1 accepting hospital during the 1-year intervention phase. They will receive the intervention, which will include utilization of the developed health information exchange platform to transfer clinical information between transferring and accepting hospital. The intervention will not interact directly with the patient, but rather their clinical data.
Group II: BaselineActive Control1 Intervention
The baseline arm will include all included patient transfers from the 3 participating transfer hospitals to the 1 accepting hospital during the 1-year pre-intervention phase. They will not receive any intervention, but rather usual care

Find a Location

Who is running the clinical trial?

Agency for Healthcare Research and Quality (AHRQ)FED
406 Previous Clinical Trials
6,756,166 Total Patients Enrolled
Brigham and Women's HospitalLead Sponsor
1,664 Previous Clinical Trials
11,833,986 Total Patients Enrolled
4 Trials studying Rheumatic Diseases
1,367 Patients Enrolled for Rheumatic Diseases

Media Library

Health Information Exchange (HIE) platform Clinical Trial Eligibility Overview. Trial Name: NCT05443321 — N/A
Rheumatic Diseases Research Study Groups: Baseline, Intervention
Rheumatic Diseases Clinical Trial 2023: Health Information Exchange (HIE) platform Highlights & Side Effects. Trial Name: NCT05443321 — N/A
Health Information Exchange (HIE) platform 2023 Treatment Timeline for Medical Study. Trial Name: NCT05443321 — N/A
~107 spots leftby Mar 2025